Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Eur J Hum Genet. 2018 Jun;26(6):848-857. doi: 10.1038/s41431-018-0111-9. Epub 2018 Feb 26.
This observational study aimed to investigate whether the reported association between family history (FH) of breast cancer (BC) or ovarian cancer (OC) and OC risks in BRCA1/2 mutation carriers can be explained by mutation position on the gene. In total, 3310 female BRCA1/2 mutation carriers participating in a nationwide prospective cohort (Hereditary Breast and Ovarian Cancer in the Netherlands) were included. FH was classified according to cancer occurrence in first-degree relatives (BC only, OC only, both, neither) and mutations were classified according to their position on the gene (OC cluster region (OCCR), BC cluster region, neither). The main outcome was OC occurrence. Cox proportional-hazard models were applied to investigate the association between FH and OC risks before and after adjusting for mutation position. Of all women included, 202 were diagnosed with OC. A BC-only FH tended to be associated with lower OC risks when compared with a FH without BC/OC (HR: 0.79, 95% CI: 0.52-1.17; HR: 0.59, 95% CI: 0.33-1.07 for BRCA1 and BRCA2, respectively) while an OC-only FH tended to be associated with higher risks (HR: 1.58, 95% CI: 0.90-2.77; HR: 1.75, 95% CI: 0.70-4.37 for BRCA1 and BRCA2, respectively). After adjusting for mutation position, association between FH and OC risks was slightly smaller in magnitude (HR: 0.85, 95% CI: 0.55-1.30; HR: 0.64, 95% CI: 0.34-1.21 for BC-only FH in BRCA1 and BRCA2, respectively; HR: 1.46, 95% CI: 0.80-2.68; HR: 1.49, 95% CI: 0.44-4.02 for OC-only FH in BRCA1 and BRCA2, respectively), indicating that mutation position explains only part of the association. Considering the magnitude of the observed trend, we do not believe FH should be used to change counseling regarding OC prevention.
这项观察性研究旨在探讨家族史(FH)与乳腺癌(BC)或卵巢癌(OC)之间的报告关联,是否可以通过基因突变位置来解释。该研究共纳入了 3310 名参与全国前瞻性队列研究(荷兰遗传性乳腺癌和卵巢癌)的女性 BRCA1/2 基因突变携带者。FH 根据一级亲属癌症发生情况进行分类(BC 仅、OC 仅、两者均有、两者均无),突变根据基因位置进行分类(OC 簇区(OCCR)、BC 簇区、两者均无)。主要结局是 OC 的发生。应用 Cox 比例风险模型研究 FH 与 OC 风险之间的关联,该关联在调整突变位置之前和之后进行分析。在所有纳入的女性中,有 202 人被诊断为 OC。与无 BC/OC 的 FH 相比,BC 仅 FH 倾向于与较低的 OC 风险相关(HR:0.79,95%CI:0.52-1.17;HR:0.59,95%CI:0.33-1.07,分别用于 BRCA1 和 BRCA2),而 OC 仅 FH 倾向于与更高的风险相关(HR:1.58,95%CI:0.90-2.77;HR:1.75,95%CI:0.70-4.37,分别用于 BRCA1 和 BRCA2)。调整突变位置后,FH 与 OC 风险之间的关联幅度略有减小(HR:0.85,95%CI:0.55-1.30;HR:0.64,95%CI:0.34-1.21,用于 BRCA1 和 BRCA2 中的 BC 仅 FH;HR:1.46,95%CI:0.80-2.68;HR:1.49,95%CI:0.44-4.02,用于 BRCA1 和 BRCA2 中的 OC 仅 FH),表明突变位置仅解释了部分关联。考虑到观察到的趋势幅度,我们认为 FH 不应该用于改变 OC 预防咨询。